Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery
Journal of the American Chemical Society · 2025
DOI: 10.1021/jacs.5c11092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Ridvan Nepravishta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, U.K. Hauptthemen laut MEDLINE: Drug Discovery, Nuclear Magnetic Resonance, Biomolecular. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Engineering and Physical Sciences Research Council, Ministerio de Ciencia, Innovaci?n y Universidades, Junta de Andaluc?a.
Abstract (Originalsprache)
Fragment-Based Drug Discovery (FBDD) is a powerful strategy used in the development of new therapeutics. Molecular fragments are screened against a target protein, where interactions are typically characterized by a low affinity. Nuclear Magnetic Resonance (NMR) spectroscopy is well-suited to detect weak protein-ligand interactions and is therefore often used in FBDD. However, while NMR is very effective in initial screening, follow-up NMR experiments to measure binding affinities (i.e., KD values) are labor-intensive and time-consuming. To address this challenge, we have developed an innovative SHARPER NMR fragment scoring technique. The high sensitivity of SHARPER NMR dramatically reduces the data acquisition times, allowing faster and more accurate quantification of fragment KD values from ligand titration curves. To further accelerate fragment scoring, a machine learning model was developed that accurately ranks fragment affinities from only two SHARPER titration points. The resulting integrated method, termed "ML-boosted 1H LB SHARPER NMR", produced significant time savings; using a 600 MHz QCI cryoprobe, KD values of up to 144 ligands in a day could be determined under our conditions, compared with only a handful achievable by traditional approaches. The proposed methodology will shorten the transition from hits to lead compounds, accelerating the drug discovery process by rapidly and reliably evaluating fragment binding, providing informed decision-making in the early stages of FBDD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Research Horizons, CRUK Scotland Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, U.K.
- Instituto de Investigaciones Químicas (IIQ), CSIC - Universidad de Sevilla, Av. Américo Vespucio 49, Seville 41092, Spain.
- EaStCHEM School of Chemistry, University of Edinburgh, David Brewster Rd, Edinburgh EH9 3FJ, U.K.
ORCID-Profile: Ridvan Nepravishta, Juan C Munoz-Garcia, Jesús Angulo, Dušan Uhrín
Förderung
- Engineering and Physical Sciences Research Council
- Ministerio de Ciencia, Innovaci?n y Universidades
- Junta de Andaluc?a
Zitieren
APA
Nepravishta, R., Munoz-Garcia, J. C., Cameron, K., Angulo, J., & Uhrín, D. (2025). Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c11092
Vancouver
Nepravishta R, Munoz-Garcia JC, Cameron K, Angulo J, Uhrín D. Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c11092
BibTeX
@article{Nepravishta2025,
author = {Nepravishta, Ridvan and Munoz-Garcia, Juan C and Cameron, Kenneth and Angulo, Jesús and Uhrín, Dušan},
title = {Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery},
journal = {Journal of the American Chemical Society},
year = {2025},
doi = {10.1021/jacs.5c11092}
}
EUVIMED